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Safety and effectiveness of bronchial thermoplasty after
10 years in patients with persistent asthma (BT10+):
a follow-up of three randomised controlled trials
Rekha Chaudhuri, Adalberto Rubin, Kaharu Sumino, Jose Roberto Lapa e Silva, Robert Niven, Salman Siddiqui, Karin Klooster, Charlene McEvoy,
Pallav L Shah, Michael Simoff, Sumita Khatri, Richard Barbers, G Mark Grubb, Edmund A McMullen, Jennifer L Olson, Michel Laviolette, on behalf
of the BT10+ Study Group*

Summary

Background Bronchial thermoplasty is an endoscopic treatment for uncontrolled asthma. Previous randomised
clinical trials have shown that bronchial thermoplasty reduces severe exacerbations in people with asthma. However,
the long-term efficacy and safety of bronchial thermoplasty beyond 5 years is unknown. The BT10+ study aimed to
investigate the efficacy and safety of bronchial thermoplasty after 10 or more years of follow-up.
Methods BT10+ was an international, multicentre, follow-up study of participants who were previously enrolled in the
AIR, RISA, and AIR2 trials and who had 10 or more years of follow-up since bronchial thermoplasty treatment. Data
on patient demographics, quality of life, lung function, CT scans (AIR2 participants only), severe exacerbations, and
health-care use during the previous year were collected at the BT10+ 10-year outcomes study visit. The primary
effectiveness endpoint was durability of the thermoplasty treatment effect, determined by comparing the proportion
of participants who had severe exacerbations during the first and fifth years after bronchial thermoplasty treatment
with the proportion of participants who had severe exacerbations during the 12-month period before the BT10+ visit.
The primary safety endpoint was the absence of clinically significant post-treatment respiratory image changes after
bronchial thermoplasty, defined as bronchiectasis or bronchial stenosis as confirmed by pulmonary volumetric highresolution CT scan at the BT10+ visit (AIR2 participants only). All analyses were done on an intention-to-treat basis.
The trial is registered with ClinicalTrials.gov, NCT03243292. The last patient was enrolled on Dec 11, 2018. The last
patient completed follow-up on Jan 10, 2019.
Findings The BT10+ study enrolled 192 (45%) of the 429 participants who were enrolled in the AIR, RISA, and AIR2
trials. The BT10+ participants comprised 136 who received bronchial thermoplasty (52% of the 260 participants who
received bronchial thermoplasty in the original trials), and 56 sham or control participants (33% of 169 from the original
trials). 18 (32%) sham or control participants received bronchial thermoplasty after the previous trials concluded. The
participants included in BT10+ were followed for 10·8–15·6 years (median 12·1 years) post-treatment. Baseline
characteristics were similar between participants enrolled in BT10+ and those not enrolled. Participants treated with
bronchial thermoplasty had similar proportions of severe exacerbations at the BT10+ visit (34 [25%] of 136 participants)
compared with 1 year (33 [24%] of 135 participants; difference 0·6%, 95% CI –9·7 to 10·8) and 5 years (28 [22%] of
130 participants; difference 3·5%, –6·7% to 13·6) after treatment. Quality of life measurements and spirometry were
similar between year 1, year 5, and the BT10+ visit. At the BT10+ study visit, pulmonary high-resolution CT scans from
AIR2 participants treated with bronchial thermoplasty showed that 13 (13%) of 97 participants had bronchiectasis.
When compared with baseline high-resolution CT scans, six (7%) of 89 participants treated with bronchial thermoplasty
who did not have bronchiectasis at baseline had developed bronchiectasis after treatment (5 classified as mild, 1 classified
as moderate). Participants treated with bronchial thermoplasty after the original study and participants in the sham or
control group also had reductions in severe exacerbations at the BT10+ visit compared with baseline.
Interpretation Our findings suggest that efficacy of bronchial thermoplasty is sustained for 10 years or more, with an
acceptable safety profile. Therefore, bronchial thermoplasty is a long-acting therapeutic option for patients with
asthma that remains uncontrolled despite optimised medical treatment.
Funding Boston Scientific.
Copyright ©2021 Elsevier Ltd. All rights reserved.

Introduction
Asthma affects around 334 million people worldwide,
leading to reduced quality of life and substantial
economic burden.1 Some asthmatics have persistent

symptoms and exacerbations despite optimal medical
therapy.
Excessive constriction and hypertrophy of airway smooth
muscle contributes to bronchial hyper-responsiveness
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Research in context
Evidence before this study
Bronchial thermoplasty is the only US Food and Drug
Administration-approved non-pharmacological procedure for
the treatment of patients aged 18 years and older with severe
persistent asthma that is not well controlled with inhaled
corticosteroids and long-acting β-agonists. During the
bronchial thermoplasty procedure, radiofrequency energy is
used to heat the airway walls in a controlled manner. Pretolani
and colleagues attributed the mechanism of action to a lasting
reduction in airway smooth muscle mass and airway nerve
endings after the procedure, as well as downstream mechanical
and physiological actions resulting from these reductions.
We searched MEDLINE between Jan 1, 1990, and Jan 1, 2020,
for clinical trials involving bronchial thermoplasty for asthma,
using the search terms “bronchial thermoplasty”, “asthma”, and
“clinical trial”. The search was limited to publications in English.
Our search retrieved several good quality results. Three previous
randomised trials (AIR, RISA, and AIR2) investigating the safety
and efficacy of bronchial thermoplasty showed that participants
undergoing the procedure had improvements in asthma
control up to 5 years after treatment, as indicated by decreased
numbers of asthma exacerbations, hospital emergency
department visits, and admissions to hospital, as well as
improved quality of life as measured by Asthma Quality of Life
Questionnaire scores. Additionally, the PAS2 study is an
ongoing, prospective, multicentre, observational study
designed to investigate the safety and efficacy of bronchial
thermoplasty outside the confines of a randomised trial, and

and airflow obstruction. Bronchial thermoplasty is a nonpharmacological, bronchoscopic, catheter-based treatment
approved for patients aged 18 years and older with severe
persistent asthma that is not well controlled with longacting β-agonists and inhaled corticosteroids. During the
bronchial thermoplasty procedure, radiofrequency energy
is used to heat the airway walls in a controlled manner,2
which leads to a reduction in airway smooth muscle mass
and bronchial nerve endings.3–7
Three randomised clinical trials of bronchial
thermoplasty have been done in participants with
moderate to severe asthma: the Asthma Intervention
Research (AIR) trial,8 the Asthma Intervention
Research-2 (AIR2) trial,9–12 and the Research in Severe
Asthma (RISA) trial.13 In these trials, participants who
underwent bronchial thermoplasty had significantly
improved clinical outcomes, including decreased
numbers of severe asthma exacerbations, hospital
emergency department visits, and admissions to
hospital, as well as improved quality of life after the
procedure. These trials showed that improvements in
asthma control after bronchial thermoplasty persisted
for 5 years.
To our knowledge, the BT10+ study is the first to follow
up participants treated with bronchial thermoplasty
458

interim results from this study indicated that, while the PAS2
study enrolled participants with more severe asthma than the
AIR2 trial, participants had reductions in severe exacerbations
and lower health-care service use compared with the 12 months
before enrolment in PAS2. However, data on long-term (more
than 5 years) safety and efficacy of bronchial thermoplasty are
lacking, and studies designed to address this are needed.
Added value of this study
To our knowledge, the BT10+ study is the first to follow up a
large group of participants treated with bronchial thermoplasty
beyond 5 years. The study was designed to follow participants
from the RISA, AIR, and AIR2 trials for 10 years or more after
treatment to evaluate the long-term durability of the
improvements in asthma control seen in previous studies.
The study was also designed to address long-term safety
concerns associated with bronchial thermoplasty, such as
diminution of treatment effect and the development of
bronchiectasis. We showed that, in participants from the AIR,
RISA, and AIR2 trials, the efficacy of bronchial thermoplasty was
sustained over 10 years.
Implications of all the available evidence
Long-term (>10 years) evidence suggests that bronchial
thermoplasty is a safe and effective non-pharmacological
therapy for asthma, and can be considered as a treatment
option for patients whose asthma remains uncontrolled despite
optimised medical therapy.

beyond 5 years. The study followed up participants from
the previous randomised trial for 10 or more years after
bronchial thermoplasty treatment to evaluate the longterm durability of improvements in asthma control and
to address long term concerns, such as diminution of
treatment effect and development of bronchiectasis.

Methods

Study design and participants
The BT10+ study was an international, multicentre,
prospective, follow-up study of participants who were
enrolled in the AIR, RISA, and AIR2 trials. BT10+ began
enrolment on Dec 11, 2017, at 16 hospitals in the USA, the
UK, Canada, Brazil, and the Netherlands that had enrolled
three or more bronchial thermoplasty participants from
the previous trials (figure 1). The study was approved by
the ethics committees at each participating hospital and
all participants signed written informed consent.
An enrolment requirement of BT10+ was previous
participation in the AIR,8 AIR2,9–12 or RISA trials.13
Participants from the previous trials were contacted by the
enrolling sites to determine if they were interested in
participating in the BT10+ study. Participants who
underwent bronchial thermoplasty treatment in these
trials at least 10 years ago were invited to participate.
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Control or sham treated participants from the
previous trials were also invited; the enrolment
requirement for the control or sham participants in BT10+
was also participation in one of the previous trials as a
control or sham participant. The control group in the AIR
and RISA studies received standard asthma therapy, as
per the local standard of treatment practice at each clinical
site. Sham participants from the AIR2 trial underwent
bronchoscopy procedures identical to those performed
in bronchial thermoplasty participants with an inactive
bronchial thermoplasty catheter. Control and sham
participants were enrolled in the BT10+ study regardless
of whether they received bronchial thermoplasty treatment
after their participation in the original studies but before
their enrolment in BT10+. Enrolment was delayed
by 4 weeks if participants had a severe exacerbation or
chest infection. A full description of the inclusion and
exclusion criteria for the BT10+ study can be found in the
study protocol online.
The inclusion and exclusion criteria for the original
AIR,8,14 RISA,13 and AIR211 trials were previously published;
for a brief summary of the enrolment criteria for each of
these trials see the appendix (p 5).

Procedures
Bronchial thermoplasty participants in the previous trials
were followed up for 5 years after bronchial thermoplasty
treatment and control or sham participants were followed
up for 1 year. Historical data from AIR, RISA, and AIR2
were used for analysis of outcomes during years 1–5; data
from the BT10+ visit were used for analysis of 10-year
outcomes. Participants underwent the following assess
ments: medical history, review of clinical notes to collect
data on comorbidities, exacerbations, and pulmonary
medication use before and at the BT10+ visit, chest
high-resolution CT (AIR2 participants, as only AIR2
participants underwent CT imaging at baseline), prebronchodilator and post-bronchodilator spirometry, lung
volumes and diffusion capacity measurements, partici
pant questionnaires (Asthma Quality of Life Questionnaire
[AQLQ] and Asthma Control Questionnaire [ACQ]),
satisfaction survey, and physical examination by a
physician. These assessments were completed in a single
visit or within 30 days.

Outcomes
The primary effectiveness endpoint in the BT10+ study
was durability of the thermoplasty treatment effect,
determined by comparing the proportion of participants
who had severe exacerbations during the first and
fifth years after bronchial thermoplasty treatment
with the proportion of participants who had severe
exacerbations during the 12-month period before the
BT10+ visit. Severe exacerbations were defined as a selfreported worsening of asthma symptoms requiring the
use of systemic corticosteroids or an increase in the
dose of maintenance systemic corticosteroids as defined

260 bronchial thermoplasty participants enrolled at 33 sites
15 from RISA
55 from AIR
190 from AIR2
216 followed up for 5 years
12 from RISA
42 from AIR
162 from AIR2

11 sites excluded with ≤2 bronchial thermoplasty patients with 5-year
follow-up (27 participants enrolled, 14 participants followed up
to 5 years)

22 sites invited to participate in BT10+ based on having ≥3 bronchial
thermoplasty patients with 5-year follow-up (233 participants enrolled,
202 participants followed up at 5 years, 31 participants not followed up
to 5 years)

6 invited sites did not participate (34 participants enrolled,
27 participants followed up to 5 years)

16 sites participated in BT10+ (199 participants enrolled; 175 participants
followed for 5 years)

For the study protocol see
https://clinicaltrials.gov/
ProvidedDocs/92/
NCT03243292/Prot_000.pdf

63 bronchial thermoplasty participants not enrolled in BT10+
44 unreachable or moved away
16 declined to participate
3 died

136 participants enrolled in BT10+ (8 from RISA, 29 from AIR, 99 from AIR2)
130 participants completed 5-year follow-up
6 participants followed up for <5 years in previous study

Figure 1: Trial profile
Participants who received bronchial thermoplasty in previous studies and
enrolled in BT10+ are included in the figure. In addition, 56 control or sham
participants were also enrolled in BT10+, of whom 18 received bronchial
thermoplasty after participation in AIR, RISA, or AIR2, and 38 participants were
not treated (received no bronchial thermoplasty treatment).

in the National Asthma Education and Prevention
Program Guidelines.15
The primary safety endpoint of the BT10+ study was
the absence of clinically significant post-treatment
respiratory image changes after bronchial thermoplasty,
defined as bronchiectasis or bronchial stenosis as
confirmed by pulmonary volumetric high-resolution CT
at the BT10+ visit for AIR2 participants. Each highresolution CT scan was read by independent, treatmentmasked core laboratory staff (BioClinica; London, UK),
including a radiologist qualified to read chest images and
a pulmonologist qualified to interpret the radiologist’s
findings. Specifically, the radiologist and pulmonologist
diagnosed bronchiectasis based on morphological
criteria on thin-section CT scans, including bronchial
dilatation with respect to the accompanying pulmonary
artery (signet ring sign), lack of tapering of bronchi, and
identification of bronchi within 1 cm of the pleural
surface, as defined in the Fleischner Society Glossary of
Terms for Thoracic Imaging.16 This same core laboratory
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Control or sham
with no post-study
bronchial
thermoplasty
(n=38)
Age (years)

54·4 (11·8)

Control or sham
with post-study
bronchial
thermoplasty
(n=18)
54·2 (8·9)

Bronchial
thermoplasty
(n=136)

53·6 (11·4)

Sex
Female

19 (50%)

7 (39%)

Male

19 (50%)

11 (61%)

54 (40%)

Weight (kg)

80·4 (19·1)

96·5 (14·0)

83·7 (19·8)

Height (cm)

167·7 (11·3)

166·6 (8·8)

Body-mass index (kg/m²)

28·5 (5·7)

34·9 (5·2)

Meet current European Respiratory Society
and American Thoracic Society Guidelines
for Severe Asthma*

26 (68%)

13 (72%)

82 (60%)

165·2 (9·1)
30·6 (6·5)
103 (76%)

FEV1
Pre-bronchodilator, % predicted

74·4 (17·4)

73·4 (17·1)

72·9 (19·4)

Post-bronchodilator, % predicted

80·7 (16·3)

80·1 (15·2)

79·4 (18·5)

Pre-bronchodilator, measured (L)

2·3 (0·8)

2·3 (0·8)

2·2 (0·8)

Post-bronchodilator, measured (L)

2·5 (0·8)

2·5 (0·8)

2·4 (0·7)

Forced vital capacity
Pre-bronchodilator, % predicted

93·2 (16·4)

87·7 (14·1)

90·2 (15·1)

Post-bronchodilator, % predicted

97·8 (16·3)

93·2 (11·8)

96·5 (14·3)

Pre-bronchodilator, measured (L)

4·0 (1·1)

3·7 (1·0)

3·7 (0·9)

Post-bronchodilator, measured (L)

4·2 (1·1)

3·9 (1·0)

4·0 (0·9)

Residual volume, % predicted

121·2 (41·8)

121·2 (21·2)

120·9 (34·6)

Total lung capacity, % predicted

102·1 (14·7)

101·8 (13·0)

105·1 (14·0)

Data are mean (SD) or n (%). *Defined as those who take 2000 μg or more inhaled corticosteroids per day and longacting β-agonists or leukotriene modifiers or two or more severe exacerbations in the 12 months before the first
bronchial thermoplasty treatment, or had one or more admissions to hospital for asthma in the 12 months before the
first bronchial thermoplasty treatment, or who had post-bronchodilator FEV1 less than 80% and FEV1/forced vital
capacity ratio less than 0·7.18

Table 1: Baseline demographics and results of tests at BT10+ study visit

was used in the AIR2 trial and, to allow comparison, the
scans were done and read as in the AIR2 trial.
Additional endpoints were severe exacerbation rates
(exacerbations per participant per year), hospital
emergency department visits and hospital admissions
for asthma, and respiratory-related serious adverse
events, defined as any respiratory-related adverse events
that were life-threatening, led to hospital treatment or
prolonged admission to hospital, disability, or death.
Post-hoc comparisons were done between pre-treatment
and post-treatment measurements to investigate the
efficacy of bronchial thermoplasty in this current cohort.
Although severe exacerbations were recorded before
treatment only for AIR2 participants, comparisons with
post-treatment severe exacerbations included all BT10+
participants.

Statistical analysis
All analyses were done on an intention-to-treat basis.
Baseline demographics, medical history, outcomes, and
adverse events were summarised with sample size,
mean, and SD for continuous variables and percentages
460

for binary variables. Comparisons of severe exacerbations,
hospital emergency department visits, and admissions
to hospital counts between time periods were based
on a repeated measures analysis that controlled for
participants (as random effects) over time with negative
binomial errors. For the bronchial thermoplasty partici
pants, post-hoc analyses were done to compare the
proportions of participants with severe exacerbations,
hospital emergency department visits, and admissions to
hospital for several pairs of mutually exclusive subgroups.
The subgroups analysed were sex (male vs female), age
(<40 years vs ≥40 years), body-mass index (<30 kg/m² vs
≥30 kg/m²), baseline AQLQ (≤4·0 vs >4·0), baseline ACQ
(≤1·5 vs >1·5), baseline post-bronchodilator FEV1 %
predicted (≤75% vs >75%), baseline pre-bronchodilator
FEV1/forced vital capacity ratio (≤70% vs >70%),
bronchodilator reversibility (reversible vs fixed), and
number of complete thermoplasty activations (≤140 vs
>140).17 A repeated measures analysis consisting of a
generalised linear mixed model with binomial error were
fitted with factors of subgroup, time, and interaction of
subgroup and time with participants treated as random
effects. For interactions with p<0·10, time periods for
each subgroup and subgroups within time periods were
investigated. SAS version 9.4 was used for all analyses.
The trial is registered with ClinicalTrials.gov,
NCT03243292. The last patient was enrolled on
Dec 11, 2018. The last patient completed follow-up on
Jan 10, 2019.

Role of the funding source
The funder of the study participated in study design, data
analysis, data interpretation, and writing of the report.
Sites collected the data and the funder provided an
electronic data capture system for data entry. All authors
had full access to all the data in the study and had final
responsibility for the decision to submit for publication.

Results
429 participants were enrolled in the AIR, RISA, and
AIR2 trials (260 treated with bronchial thermoplasty and
169 treated with control or sham) at 33 clinical sites.
22 sites with three or more participants treated with
bronchial thermoplasty with 5 years of follow-up were
invited to participate in the BT10+ study. Six invited sites
did not participate. The 16 participating sites enrolled
199 participants treated with bronchial thermoplasty in
the previous three trials, of which 63 participants were
not enrolled in BT10+ (44 participants moved or were
unreachable, 16 declined to participate, and three died).
Thus, 136 participants treated with bronchial
thermoplasty participated in the BT10+ study (figure 1).
Additionally, 56 control or sham participants were
enrolled, of whom 18 received bronchial thermoplasty
after participation in AIR, RISA, or AIR2, and
38 participants received no bronchial thermoplasty
treatment (control or sham not treated with bronchial
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There was also a reduction in severe exacerbations in
the control or sham participants not treated with
bronchial thermoplasty, who had 0·96 (95% CI 0·53–1·39)
severe exacerbations per participant in the 12 months
before control or sham treatment, 0·39 (0·19–0·60)
severe exacerbations per participant during year 1 after
treatment, and 0·82 (0·32–1·32) severe exacerbations
per participant during the 12 months before the BT10+
study visit. In the 12 months before control or sham
treatment, 12 (50%, 95% CI 29·1–70·9) of 24 AIR2
control or sham participants not treated with bronchial
thermoplasty had severe exacerbations compared with
12 (32%, 17·5–48·7) of 38 control or sham participants
not treated with bronchial thermoplasty at year 1 after
treatment and 14 (37%, 21·8–54·0) of 38 during the
A
1·2
Events per participant

1·0

†

0·8

*

0·6
*

0·4
0·2
0

B
0·8
Events per participant

0·7
0·6
0·5
*‡

0·4
0·3
0·2

*

*

0·1
0

C
0·16
0·14
Events per participant

thermoplasty). The 192 patients included in BT10+ were
followed for 10·8–15·6 years (12·1 median) posttreatment. Table 1 lists the demographic and assessments
from the BT10+ visit for each group of participants. There
were no clinically relevant differences in baseline
characteristics between participants enrolled and not
enrolled in the BT10+ study (appendix p 7).
The most common comorbidities were gastrooesophageal reflux disease and hypertension in all three
groups (appendix p 10). Maintenance oral corticosteroid
use was reported in seven (5%) of 136 participants
treated with bronchial thermoplasty, and ten (7%) of
136 participants treated with bronchial thermoplasty
received biological medications. Maintenance oral
corticosteroid use was reported in one (3%) of 38 control
or sham participants not treated with bronchial
thermoplasty, and biological medications in three (8%) of
38 control or sham participants not treated with bronchial
thermoplasty.
In the 12 months before the BT10+ visit,
34 (25%, 95% CI 18·0 to 33·1) of 136 participants treated
with bronchial thermoplasty had severe exacerbations
(15 participants had one severe exacerbation, ten had
two severe exacerbations, and nine had three or more
severe exacerbations). These severe exacerbation
proportions were similar to those for bronchial thermo
plasty participants during the first year after treatment
(33 of 135 participants; 24%, 95% CI 17·5 to 32·6;
difference 0·6%, 95% CI –9·7 to 10·8) and during year 5
after treatment (28 of 130 participants; 22%, 14·8 to 29·6;
difference 3·5%, –6·7 to 13·6); however, proportions were
smaller compared with AIR2 bronchial thermo
plasty
participants 12 months before treatment (50 of
99 participants; 51%, 40·3 to 60·7; difference –25·5%, –37·8
to –13·3). Participants treated with bronchial thermoplasty
included in BT10+ had 0·82 (95% CI 0·62 to 1·02) severe
exacerbations per participant (AIR2 data only) 12 months
before bronchial thermoplasty treatment compared with
0·47 (0·29 to 0·64) severe exacerbations per participant
during the first year after bronchial thermoplasty
(difference –0·35, 95% CI –0·61 to –0·09; p=0·012) and
0·31 (0·19 to 0·43) severe exacerbations per participant
during year 5 after bronchial thermoplasty (–0·51,
–0·73 to –0·29; p<0·0001), both of which were significantly
reduced compared with 12 months before bronchial
thermoplasty. During the 12 months before the BT10+
visit, there were 0·58 (95% CI 0·33 to 0·83) severe
exacerbations per participant, which was significantly
more than during year 5 after bronchial thermoplasty
treatment (difference 0·27, 95% CI 0·01 to 0·56; p=0·044)
but not significantly different from year 1 after bronchial
thermoplasty treatment (difference 0·11, –0·19 to 0·42;
p=0·43; figure 2A). Thus, reductions in both the proportion
of participants with severe exacerbations after bronchial
thermoplasty and the number of severe exacerbations per
participant appear to be sustained for 10 years or more
after treatment.

0·12
0·10
0·08
0·06
*

0·04

*

0·02
0

12 months
before
bronchial
thermoplasty

Year 1

Year 2

Year 3

Year 4

Year 5

BT10+
visit

Figure 2: Severe asthma exacerbations in participants treated with bronchial thermoplasty (A), hospital
emergency department visits (B), and admissions to hospital for asthma (C) in the BT10+ study
Datapoints represent mean and 95% CIs. In part A, only participants previously enrolled in AIR2 are analysed at
12 months before treatment as this information was not collected in the RISA and AIR trials. *Significantly lower than
12 months before bronchial thermoplasty (p<0·05). †Significantly higher than year 5 (p<0·05), but not significantly
different from 12 months before bronchial thermoplasty and year 1. ‡Significantly higher than years 1 and 5 (p<0·05).
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12 months before the BT10+ visit (eight participants
had one severe exacerbation, three had two severe
exacerbations, and three had three or more severe
exacerbations). However, in the 24 sham participants
from the AIR2 trial who had baseline, 1 year, and 10 year
data, there was no change in the rate of severe
exacerbations over time.
A reduction in hospital emergency department visits
for asthma was also observed. During the 12 months
before treatment, bronchial thermoplasty participants
experienced 0·54 (95% CI 0·30 to 0·77) hospital
emergency department visits per participant compared
with 0·06 (0·01 to 0·11) hospital emergency department
visits per participant during year 1 after bronchial
thermoplasty, 0·08 (0·03 to 0·13) hospital emergency
department visits per participant during year 5 after
bronchial thermoplasty, and 0·21 (0·04 to 0·38) hospital
emergency department visits per participant during the
12 months before the BT10+ visit. Compared with the
12 months before bronchial thermoplasty, the number of
hospital emergency department visits per participant
was lower at year 1 after bronchial thermoplasty,
(difference –0·48, 95% CI –0·72 to –0·24; p<0·0001),
year 5 after bronchial thermoplasty (–0·46, –0·71 to
–0·21; p<0·0001), and during the 12 months before the
BT10+ visit (–0·32, –0·61 to –0·03; p=0·031); however,
the rate of hospital emergency department visits was
significantly higher during the 12 months before the
BT10+ visit than during year 1 (0·15, 95% CI 0·02 to
0·29; p=0·026) and year 5 (0·14, 0·02 to 0·26; p=0·024)
after bronchial thermoplasty (figure 2B). The proportion
of participants with hospital emergency department
visits was also reduced after bronchial thermoplasty.
During the 12 months before bronchial thermoplasty,
33 (24%, 95% CI 17·3% to 32·4%) of 136 participants
visited a hospital emergency departm
ent for asthma
symptoms. During year 1, year 5, and the 12 months
before the BT10+ visit, the proportions of participants
treated with bronchial thermoplasty who visited a hospital
emergency department because of asthma symptoms
were six (4%, 95% CI 1·6 to 9·4) of 135, nine (7%, 3·2 to 12·7)
of 130, and 14 (10%, 5·7 to 16·7) of 136, respectively.
A reduction in hospital emergency department visits was
also observed in control or sham participants not treated
with bronchial thermoplasty. In the 12 months before
control or sham treatment, participants had 0·34 (95% CI
0·07–0·61) hospital emergency department visits per
participant, which reduced to 0·05 (0·00–0·12) visits per
participant during year 1 after control or sham treatment
and 0·08 (0·00–0·17) visits per participant during the
12 months before the BT10+ visit. The proportion of
control or sham participants not treated with bronchial
thermoplasty who visited a hospital emergency department
for asthma symptoms after treatment reduced from seven
(18%, 95% CI 7·7–34·3) of 38 participants in the 12 months
before control or sham treatment, to two (5%, 0·6–17·7) of
38 participants at year 1 after treatment and 3 (8%, 1·7–21·4)
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of 38 participants during the 12 months before the
BT10+ visit.
Similarly, a reduction in admissions to hospital for
asthma was seen. During the 12 months before
bronchial thermoplasty treatment, the rate of
admissions to hospital for asthma in the bronchial
thermoplasty group was 0·09 (95% CI 0·03 to 0·14)
admissions to hospital per participant, which reduced
to 0·06 (0·01 to 0·11) admissions to hospital per
participant during year 1 after bronchial thermoplasty,
0·02 (0·00 to 0·04) admissions to hospital per
participant during year 5, and 0·02 (0·00 to 0·05)
admissions to hospital per participant during the
12 months before the BT10+ visit. Compared to the
12 months before bronchial thermoplasty, the rates of
admissions to hospital for asthma were lower at year 5
(difference –0·07, 95% CI –0·13 to –0·01; p=0·022)
and during the 12 months before the BT10+ visit
(–0·07, –0·13 to –0·01; p=0·016; figure 2C). During
follow-up, a reduction in the proportion of participants
treated with bronchial thermoplasty being admitted to
hospital for asthma was observed. During the
12 months before bronchial thermoplasty treatment,
ten (7%, 95% CI 3·6–13·1) of 136 participants treated
with bronchial thermoplasty were admitted to hospital.
During year 1, year 5, and the 12 months before the
BT10+ visit, the proportion of participants treated
with bronchial thermoplasty who were admitted to
hospital for asthma was six (4%, 95% CI 1·6–9·4) of
135 participants, two (2%, 0·2–5·4) of 130 participants,
and three (2%, 0·5–6·3) of 136 participants, respectively.
Although three (8%, 95% CI 1·7–21·4) of 38 control
or sham participants not treated with bronchial
thermoplasty were admitted to hospital for asthma
(0·08 admissions to hospital per participant, 95% CI
0·00–0·17) in the 12 months before control or sham
treatment, no admissions to hospital occurred during
either year 1 after treatment or during the 12 months
before the BT10+ visit.
Spirometry was done at baseline and yearly until year 5
after treatment as part of the previous studies and at the
BT10+ visit. Bronchial thermoplasty treatment did not
affect either pre-bronchodilator or post-bronchodilator
FEV1 (appendix pp 14–15).
Mean AQLQ scores increased from 4·73 (SD 1·21;
95% CI 4·53–4·94) to 5·86 (0·98; 5·69–6·03) by 12 weeks
after bronchial thermoplasty, and this improvement
was sustained for 10 years or more after treatment
(5·78, SD 1·11; 95% CI 5·59–5·97; figure 3). Similarly,
ACQ scores dropped from 1·86 (SD 0·85; 95% CI
1·71–2·00) to 1·17 (0·76; 1·04–1·29) by 12 weeks after
bronchial thermoplasty, and improvements in these
scores also persisted for 10 years or more (1·31, SD 1·00;
95% CI 1·15–1·48). Participants also completed a patient
satisfaction survey. 122 (90%, 95% CI 83·3–94·3)
of 136 patients treated with bronchial thermoplasty
stated they would undergo the procedure again and
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6·0
5·5

Bronchial thermoplasty
(n=99)

Bronchiectasis observed at baseline

3/21 (14%; 3·0–36·3)

7/96 (7%; 3·0–14·4)

Bronchiectasis observed at BT10+ visit

2/21 (10%; 1·2–30·4)

13/97 (13%; 7·3–21·8)

Bronchiectasis observed at BT10+ visit and not baseline

0/18 (0; 0–18·5)

6/89 (7%; 2·5–14·1)

Data are n/N (%; 95% CI). Sham participants receiving bronchial thermoplasty after participation in the AIR2 study
were excluded. Baseline high-resolution CT information for one AIR2 bronchial thermoplasty participant was missing
but this participant had a high-resolution CT at the BT10+ study visit.
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Table 2: Results of high-resolution pulmonary CT at the BT10+ study visit (AIR2 participants only)
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Figure 3: AQLQ (A) and ACQ (B) scores over time in participants treated with
bronchial thermoplasty
Datapoints represent mean and 95% CIs.

130 (96%, 90·6–98·4) of 136 stated they would
recommend bronchial thermoplasty to a friend or family
member.
At baseline, seven (7%, 95% CI 3·0–14·4) of 96 AIR2
participants treated with bronchial thermoplasty had
bronchiectasis (table 2). At the BT10+ study visit, 13 (13%,
95% CI 7·3–21·8) of 97 participants had bronchiectasis.
Six (7%, 95% CI 2·5–14·1) of 89 participants treated with
bronchial thermoplasty who did not have bronchiectasis at
baseline developed bronchiectasis after treatment. All but
one instance of bronchiectasis was classified as mild; one
case was classified as moderate. Clinical symptoms of
bronchiectasis (chronic cough, increased sputum, and re
current infections) were not present in these participants.
At baseline, 3 (14%, 95% CI 3·0–36·3) of 21 AIR2 sham
participants had bronchiectasis, and at the BT10+ visit,
two (10%, 1·2–30·4) of 21 had evidence of bronchiectasis
(table 2). None of the sham participants developed
bronchiectasis after sham treatment.
We analysed several pairs of mutually exclusive
subgroups of participants treated with bronchial
thermoplasty using a generalised linear mixed model to
see if bronchial thermoplasty was effective in reducing
the proportion of participants with severe exacerbations,
hospital emergency department visits, and admissions
to hospital over time and to see if there were any
differences between the subgroup pairs. For severe
exacerbations and hospital emergency department visits,

our analysis showed there was a significant decrease
in both outcome measures over time for all sets of
subgroups (figure 4; appendix pp 12, 16), and nearly all
subgroups of participants treated with bronchial
thermoplasty benefited (appendix p 6).
Based on a composite definition of a bronchial
thermoplasty responder (participants with neither severe
exacerbations nor admissions to hospital for asthma in
the year before the BT10+ study and taking neither
maintenance corticosteroids nor monoclonal antibodies at
the BT10+ visit), 93 (68%) of 136 participants treated with
bronchial thermoplasty were responders in this post-hoc
analysis. Within the subgroups, younger participants had
a higher proportion of responders than older participants
(51 [76%] of 67 participants aged ≤40 years vs 42 [61%] of
69 participants aged >40 years), participants with lower
baseline AQLQ responded more often than those with
higher baseline AQLQ (30 [83%] of 36 participants with
score ≤4 vs 62 [64%] of 97 partici
pants with score >4
[baseline AQLQ data were missing for three participants]),
and participants with higher post-bronchodilator FEV1
had more responders than those with lower postbronchodilator FEV1 (25 [57%] of 44 participants with
baseline post-bronchodilator FEV1 % predicted ≤75 vs
68 [74%] of 92 participants with baseline postbronchodilator FEV1 % predicted >75). Additionally, there
were more responders with fixed (70 [73%] of 96 partici
pants) versus reversible (23 [58%] of 40 participants)
obstructive airway disease, and participants with more
treatment activations responded more often (40 [61%] of
66 participants for ≤140 complete activations vs 53 [76%] of
70 participants for >140 complete activations).
There were no adverse events after patients consented
to the BT10+ study. Respiratory events in the year before
the BT10+ visit are included in table 3 and the
appendix (p 17). These events were not thought to be
associated with bronchial thermoplasty by the study
investigators.
Two deaths occurred during the previous studies,
and both were unrelated to bronchial thermoplasty.
One participant treated with bronchial thermoplasty in
the AIR2 study died in a motor vehicle accident, and one
patient treated with bronchial thermoplasty in the RISA
study died of acute intoxication with γ-hydroxybutyrate.
Two additional participants treated with bronchial
thermoplasty died after the previous studies completed
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Figure 4: Subgroup responder analyses of severe asthma exacerbations after bronchial thermoplasty for participants aged ≤40 years vs ≥41 years, participants
with BMI ≤30 kg/m² or vs >30 kg/m², participants with AQLQ scores >4 vs ≤4, participants with reversible vs fixed obstructive airway disease, participants
with post-bronchodilator FEV1 ≤75% vs >75%, and participants receiving ≤140 activations vs ≥141 activations
AQLQ=Asthma Quality of Life Questionnaire. BMI=body-mass index.

(neither related to the bronchial thermoplasty procedure).
One participant treated with bronchial thermoplasty in
the RISA study died from pneumonia and one participant
treated with bronchial thermoplasty in the AIR2 study
died from metastasis of primary renal cancer.
No control or sham group participants died during
the AIR, RISA, and AIR2 trials. However, one AIR2
participant treated with the sham procedure died after
the study, with an unspecified violent death.

Discussion
Previous randomised trials have shown that bronchial
thermoplasty significantly improved quality of life scores,
including AQLQ and ACQ, and decreased severe
exacerbations, hospital emergency department visits,
and admissions to hospital. These improvements were
observed up to 5 years after bronchial thermoplasty. The
464

BT10+ study shows that participants treated with
bronchial thermoplasty had sustainable improvements
in severe exacerbations and other health-care use
outcomes for 10 or more years of follow-up. At the
BT10+ study visit, the rates of severe exacerbations
and hospital emergency department visits were higher
compared with data collected at year 5, but the positive
effect compared with baseline was sustained, as was the
improvement in AQLQ and ACQ up to 10 years.
The BT10+ study found that participants in the control
group had decreases in severe exacerbations, hospital
emergency department visits, and admissions to hospital.
This placebo effect has been reported for other studies,
including the AIR2 trial,12 but we believe that a placebo
effect is unlikely to last for 10 years or more. In the
BT10+ study, we were able to regain contact with only
56 (33%) of 169 control or sham group participants and
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18 of these received bronchial thermoplasty after their
original study. However, the small number of control
or sham group participants does not fully explain the
effect seen in this study, which might be within the
natural variation of asthma, but this aspect needs further
investigation.
In BT10+, FEV1 remained relatively consistent over time.
People with severe asthma have a progressive decline of
22·5–50 mL per year in FEV119–23 (appendix pp 14–15), and
the measured FEV1 in participants treated with bronchial
thermoplasty from AIR, RISA, and AIR2 suggests FEV1
might not have declined as rapidly as would be expected in
participants not receiving this treatment.
Because the previous randomised trials were not
designed to capture the data required to predict responses
to bronchial thermoplasty, we were unable to do an analysis
to identify likely responders to bronchial thermoplasty.
However, our subgroup analysis showed that all groups of
several mutually exclusive subsets of patients had a
reduction in severe exacerbations, hospital emergency
department visits, and admissions to hospital from the
time of bronchial thermoplasty treatment to the most
recent BT10+ study. It is encouraging to find that a variety
of patients benefit from bronchial thermoplasty, although
the sample size in this study did not allow us to show
differences between groups for most factors. However,
there seemed to be an improvement in outcomes for
patients with more than 140 activations over the three
bronchial thermoplasty treatments compared with patients
with 140 or fewer activations, and there was a better
response for those younger than 40 years compared with
those older than 40 years, those with higher baseline postbronchodilator FEV1 and those with poorer baseline
asthma quality of life scores.
The question of whether bronchial thermoplasty
induces clinically significant respiratory changes, such as
bronchiectasis, over the long term has not been addressed.
High-resolution CT scans from BT10+ participants
revealed that although none of the sham participants
developed bronchiectasis during the time period between
high-resolution CT scans, six (7%) participants treated
with bronchial thermoplasty appeared to develop bron
chiectasis over the same time period. This bronchiectasis
was mostly mild and might not necessarily be attributable
to bronchial thermoplasty treatment. An alternative
explanation for the slight increase in participants with
bronchiectasis at the BT10+ study visit could be related to
improvements in both CT hardware and image processing
algorithms developed over the past decade that could result
in better detection of mild bronchiectasis compared with
older images. When baseline high-resolution CT was done
on AIR2 patients, the scans consisted of interval slices
rather than volume high-resolution CT. Thus, comparison
of airway volumes between the BT10+ and baseline scans
is not possible. Finally, several studies have shown that
airway dilation, often transient, can be observed after
bronchial thermoplasty, and this is associated with reduced

Control or sham
(n=38)

Bronchial thermoplasty
(n=136)

Events*

Participants
with event

Events*

Participants
with event

Total

5

5 (13%)

35

29 (21%)

Infections and infestations

1

1 (3%)

1

1 (1%)

0

0

1

1 (1%)

Bronchitis
Respiratory tract infection
Investigations
Abnormal CT scan
Respiratory, thoracic, and mediastinal disorders

1

1 (3%)

0

0

0

0

1

1 (1%)

0

0

1

1 (1%)

4

4 (11%)

33

28 (21%)

Asthma

0

0

1

1 (1%)

Atelectasis

0

0

2

1 (1%)

Bronchial wall thickening

0

0

1

1 (1%)

Bronchiectasis

3

3 (8%)

20

20 (15%)

Interstitial lung disease

0

0

1

1 (1%)

Pulmonary fibrosis

0

0

1

1 (1%)

Pulmonary hypertension

0

0

1

1 (1%)

Pulmonary mass

1

1 (3%)

5

5 (4%)

Respiratory tract inflammation

0

0

1

1 (1%)

Data are n or n (%). There were no participant deaths in the year before the BT10+ study visit. Two bronchial
thermoplasty participant deaths occurred during the previous studies and two additional bronchial thermoplasty
participants died after year 5 of the previous study but before enrolment in the BT10+ study (none were related to
the bronchial thermoplasty procedure). One sham participant from AIR2 died after the AIR2 study but before the
BT10+ study visit due to unspecified violent death. *Events numbers are the total episodes of each type of event
among all participants.

Table 3: Adverse events during the 12 months before the BT10+ study visit

airway resistance and improved asthma symptoms.24–26 It is
possible that we are observing this phenomenon in a
delayed fashion in a small number of scans in the BT10+
study rather than the development of true bronchiectasis,
particularly since the BT10+ investigators have noted that
these participants did not display any clinically relevant
symptoms of bronchiectasis.
The BT10+ study has several other important limitations.
First, because of the length of time between participation
in the three original trials and BT10+, several participants
from the original trials were lost to follow-up and could not
be enrolled in the BT10+ study. Although our findings
suggest that there were no clinically relevant differences in
demographics and characteristics between participants
who were enrolled in BT10+ and those who were not, it is
possible that selection bias might have occurred.
Additionally, the reporting of results pertaining to severe
exacerbations was based on patient recollection supported
by case note reviews by investigators, similar to the
methodology used for baseline data from the original
trials. Bronchial thermoplasty is only recommended for
use in patients with severe asthma, and although most
participants in the BT10+ study were considered to have
severe asthma based on European Respiratory Society and
American Thoracic Society Guidelines for Severe Asthma,18
26% of participants did not fulfill these criteria. Thus, the
improvements in asthma control seen in the BT10+ study
population should be interpreted with caution and might
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not be applicable to patients with the most severe asthma
who are seen in clinical practice. Finally, this study was
funded by the manufacturer of the bronchial thermoplasty
system and three of the listed authors are full-time
employees of the manufacturer, which could potentially
lead to a perceived conflict of interest.
In conclusion, the data from the BT10+ study indicate
that the efficacy of bronchial thermoplasty is sustained
for 10 or more years and that bronchial thermoplasty has
an acceptable safety profile. This suggests that bronchial
thermoplasty is an effective non-pharmacological therapy
for patients with asthma, particularly for those whose
asthma remains uncontrolled despite optimised medical
therapy and for those who do not qualify for or respond
adequately to biologicals.
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